Christians Kathleen K, Pilgrim Charles H C, Tsai Susan, Ritch Paul, George Ben, Erickson Beth, Tolat Parag, Evans Douglas B
Department of Surgery, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI.
Department of Surgery, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI.
Surgery. 2014 May;155(5):919-26. doi: 10.1016/j.surg.2014.01.003. Epub 2014 Jan 22.
Tumor-induced arterial abutment/encasement has been traditionally a contraindication to surgery in patients with localized pancreatic cancer (PC). One recent meta-analysis reported greater mortality rates in this setting. We report herein a series of planned arterial resections in carefully selected patients who responded favorably to combined modality therapy for localized PC.
We reviewed all patients with PC and arterial encasement treated between May 2011 and September 2013; all patients received an extensive course of neoadjuvant therapy before surgery.
Of 15 patients taken to surgery, 2 had peritoneal disease at laparoscopy, and therefore, laparotomy was not performed. Pancreatectomy (pancreaticoduodenectomy, 3; distal, 8; central pancreatectomy, 1; total, 1) was performed in the remaining 13, 10 of whom required arterial resection. The most common operation was an Appleby procedure. Of 10 patients who underwent combined pancreatectomy and arterial resection, their median age was 62 years (range, 33-75), median operative time was 7.5 hours, and median blood loss was 725 mL. Complications occurred in 3 of 15 patients with no perioperative mortality. Median duration of hospital stay was 9 days (range, 5-19). An R0 resection was achieved in 11 (85%) of 13 patients. At a median follow-up of 21 months, 8 of these 13 resected patients (62%) are alive without disease.
Planned arterial resection at the time of pancreatectomy can be performed with acceptable morbidity and mortality; patient selection and induction therapy are likely critically important variables that seem to impact patient outcome. Those patients with stable or responding disease after induction therapy represent the subset of patients with potentially favorable tumor biology in whom extended resections may enhance survival duration.
肿瘤导致的动脉毗邻/包绕传统上是局部胰腺癌(PC)患者手术的禁忌证。最近一项荟萃分析报道了在此种情况下更高的死亡率。我们在此报告一系列在精心挑选的、对局部PC综合治疗反应良好的患者中进行的计划性动脉切除术。
我们回顾了2011年5月至2013年9月间接受治疗的所有PC合并动脉包绕的患者;所有患者在手术前均接受了广泛的新辅助治疗疗程。
15例接受手术的患者中,2例在腹腔镜检查时发现有腹膜疾病,因此未进行剖腹手术。其余13例患者接受了胰腺切除术(胰十二指肠切除术3例;远端胰腺切除术8例;中央胰腺切除术1例;全胰切除术1例),其中10例需要进行动脉切除术。最常见的手术是Appleby手术。10例接受胰腺切除术联合动脉切除术的患者,中位年龄为62岁(范围33 - 75岁),中位手术时间为7.5小时,中位失血量为725毫升。15例患者中有3例发生并发症,无围手术期死亡。中位住院时间为9天(范围5 - 19天)。13例患者中有11例(85%)实现了R0切除。在中位随访21个月时,这13例接受切除的患者中有8例(62%)无病存活。
在胰腺切除时进行计划性动脉切除术,其发病率和死亡率可接受;患者选择和诱导治疗可能是对患者预后有重要影响的关键变量。诱导治疗后疾病稳定或有反应的患者代表了肿瘤生物学特性可能良好的患者亚组,扩大切除术可能会延长其生存时间。